Molnupiravir, the antiviral pill developed by Merck to treat Covid-19, speeded up patients’ recovery but failed to reduce risks of hospitalisation and death, full results of an extensive UK clinical trial showed.
A peer-reviewed paper published in The Lancet confirmed preliminary findings released in October that molnupiravir — marketed by the US pharmaceutical group as Lagevrio — did not prevent the most severe disease among the 25,700 participants.
But researchers at Oxford university, who led the so-called Panoramic trial, put more emphasis on the positive secondary outcomes at a media briefing on Thursday.
您已阅读20%（616字），剩余80%（2476字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。